GPX4 and cancer: For instance, class I FINs including sorafenib and erastin, which induce ferroptosis via suppressing intracellular glutathione (GSH) synthesis to inhibit glutathione peroxidase 4 (GPX4)-mediated antioxidant reaction, have exhibited great efficacy in preclinical cancer models or clinic administration of liver cancer patients [7, 8].